NLRC5 and neoplasm: To circumvent the absence of T-cell activation or “priming”, tumor-bearing mice were pre-immunized with an infected cell vaccine (ICV) consisting of irradiated ID8-p53−/− NLRC5+/− cells infected ex vivo with the oncolytic virus VSVΔ51 and compared with the parental control mice (Supplementary Figure 7H).